JP2017528457A - 酢酸アビラテロン製剤及び使用方法 - Google Patents

酢酸アビラテロン製剤及び使用方法 Download PDF

Info

Publication number
JP2017528457A
JP2017528457A JP2017512783A JP2017512783A JP2017528457A JP 2017528457 A JP2017528457 A JP 2017528457A JP 2017512783 A JP2017512783 A JP 2017512783A JP 2017512783 A JP2017512783 A JP 2017512783A JP 2017528457 A JP2017528457 A JP 2017528457A
Authority
JP
Japan
Prior art keywords
abiraterone acetate
less
dosage form
dose
unit dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528457A5 (enExample
Inventor
モーラ・マーフィー
ポール・ネメス
ウィリアム・エイチ・ボッシュ
マシュー・カラハン
サチャ・バーミディパティ
ジェイソン・コールマン
クリストファー・ヒル
マーク・ノレット
Original Assignee
イシューティカ インコーポレイテッド
イシューティカ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2017528457(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed by イシューティカ インコーポレイテッド, イシューティカ インコーポレイテッド filed Critical イシューティカ インコーポレイテッド
Publication of JP2017528457A publication Critical patent/JP2017528457A/ja
Publication of JP2017528457A5 publication Critical patent/JP2017528457A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
JP2017512783A 2014-09-18 2015-09-18 酢酸アビラテロン製剤及び使用方法 Pending JP2017528457A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US62/052,294 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
US14/707,922 2015-05-08
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Publications (2)

Publication Number Publication Date
JP2017528457A true JP2017528457A (ja) 2017-09-28
JP2017528457A5 JP2017528457A5 (enExample) 2018-10-18

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512783A Pending JP2017528457A (ja) 2014-09-18 2015-09-18 酢酸アビラテロン製剤及び使用方法

Country Status (17)

Country Link
EP (1) EP3193857A4 (enExample)
JP (1) JP2017528457A (enExample)
KR (2) KR102491439B1 (enExample)
CN (1) CN106687112A (enExample)
AP (1) AP2017009804A0 (enExample)
AU (1) AU2015317466A1 (enExample)
BR (1) BR112017003219A2 (enExample)
CA (1) CA2958316A1 (enExample)
CO (1) CO2017002472A2 (enExample)
EA (1) EA201790650A1 (enExample)
IL (1) IL250270B (enExample)
MD (1) MD20170048A2 (enExample)
MX (1) MX2017003525A (enExample)
PH (1) PH12017500239A1 (enExample)
SG (1) SG11201701139YA (enExample)
TN (2) TN2017000098A1 (enExample)
WO (1) WO2016044701A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521498A (ja) * 2020-04-16 2023-05-24 タバンタ セラピューティクス ハンガリー インコーポレイティド 前立腺がんを治療するための方法及び組成物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
WO2018187728A1 (en) 2017-04-07 2018-10-11 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
EP3914234A4 (en) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. PHARMACEUTICAL COMPOSITIONS
DK3935068T3 (da) 2019-03-06 2023-12-04 Propella Therapeutics Inc Abirateron-prodrugs
CN110742870B (zh) * 2019-12-04 2021-04-20 武汉大学 醋酸阿比特龙制剂及其制备方法
CN111110646A (zh) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 一种低规格醋酸阿比特龙口服制剂的处方及制备方法
CN113384542B (zh) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法
WO2021224471A1 (en) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Pharmaceutical formulations of abiraterone acetate and niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
WO2022174134A1 (en) 2021-02-15 2022-08-18 Propella Therapeutics, Inc. Abiraterone prodrugs
KR20240044329A (ko) 2022-09-28 2024-04-04 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 경구용 복합정제
KR20240145412A (ko) 2023-03-27 2024-10-07 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 약제학적 제제 및 이의 제조방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524718A (ja) * 2009-04-24 2012-10-18 イシューティカ ピーティーワイ リミテッド 商業的規模での封入ナノ粒子の製造
WO2013164473A1 (en) * 2012-05-04 2013-11-07 Jagotec Ag Pharmaceutical composition comprising abiraterone acetate
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
CN102743393A (zh) * 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
CN105246598B (zh) * 2013-03-15 2019-09-13 太阳药业环球公司 乙酸阿比特龙酯制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524718A (ja) * 2009-04-24 2012-10-18 イシューティカ ピーティーワイ リミテッド 商業的規模での封入ナノ粒子の製造
WO2013164473A1 (en) * 2012-05-04 2013-11-07 Jagotec Ag Pharmaceutical composition comprising abiraterone acetate
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521498A (ja) * 2020-04-16 2023-05-24 タバンタ セラピューティクス ハンガリー インコーポレイティド 前立腺がんを治療するための方法及び組成物

Also Published As

Publication number Publication date
KR102491439B1 (ko) 2023-01-25
MX2017003525A (es) 2017-06-21
PH12017500239A1 (en) 2017-07-03
KR102617537B1 (ko) 2023-12-22
EP3193857A1 (en) 2017-07-26
SG11201701139YA (en) 2017-03-30
AU2015317466A1 (en) 2017-02-23
KR20230014878A (ko) 2023-01-30
MD20170048A2 (ro) 2017-08-31
CO2017002472A2 (es) 2017-07-11
BR112017003219A2 (pt) 2017-11-28
AP2017009804A0 (en) 2017-03-31
IL250270B (en) 2021-02-28
IL250270A0 (en) 2017-03-30
CA2958316A1 (en) 2016-03-24
EP3193857A4 (en) 2018-04-11
TN2017000098A1 (en) 2018-10-19
CN106687112A (zh) 2017-05-17
WO2016044701A1 (en) 2016-03-24
KR20170070025A (ko) 2017-06-21
TN2018000318A1 (en) 2020-01-16
EA201790650A1 (ru) 2017-07-31

Similar Documents

Publication Publication Date Title
JP7752150B2 (ja) アビラテロン酢酸エステル製剤
JP2017528457A (ja) 酢酸アビラテロン製剤及び使用方法
US9889144B2 (en) Abiraterone acetate formulation and methods of use
US10292990B2 (en) Abiraterone steroid formulation
HK40018807A (en) Abiraterone acetate formulation
HK40018807B (en) Abiraterone acetate formulation
HK40020084B (zh) 乙酸阿比特龙酯制剂
HK1234990A1 (en) Abiraterone acetate formulation and methods of use
HK1220162B (en) Abiraterone acetate formulation
OA18169A (en) Abiraterone acetate formulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180907

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190514

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200107